Rachel McMinn

In a report published Friday, Bank of America Merrill Lynch analyst Rachel McMinn reiterated Buy on Intercept Pharmaceuticals (NASDAQ: ICPT), raising its price objective to $872.00 from $81.00 According to the report, the price objective rise is driven by the analyst's revised model which now...

In a report published Tuesday, Bank of America analyst Rachel McMinn maintained a Buy rating on Puma Biotechnology (NYSE: PBYI), raising price target to $141.00 from $118.00 due to higher probability. According to the report, “PBYI hosted an investor call to provide an update on three ongoing...

In a report published Monday, Bank of America analyst Rachel McMinn reiterated an Underperform rating on Ariad Pharmaceuticals (NASDAQ: ARIA), and raised the price target from $2.00 to $3.00. In the report, Bank of America noted, “ARIA announced on Friday that it and the FDA have agreed on a...

In a report published Thursday, Bank of America analyst Rachel McMinn initiated coverage on Relypsa (NASDAQ: RLYP) with a Buy rating and $40.00 price target. In the report, Bank of America noted, “We are initiating coverage of Relypsa (RLYP) with a Buy rating and a $40 price objective. We view...

On Friday, Bank of America Merrill Lynch analyst Rachel McMinn increased the price objective for Gilead Sciences Inc. (NASDAQ: GILD) from $96 to $107. McMinn expects an increase in share price, "as investors gain visibility on HCV pricing in late 2013, obtain Phase 3 data in early 2014, observe...

In a report published Thursday, Bank of America analyst Rachel McMinn downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Buy to Neutral, and lowered the price target from $24.00 to $7.00. In the report, Bank of America noted, “We rate ARIA a Neutral based on our view that...

In a report published Monday, Bank of America analyst Rachel McMinn downgraded the rating on Achillion Pharmaceuticals (NASDAQ: ACHN) from Buy to Underperform, and lowered the price target from $10.00 to $2.00. In the report, Bank of America noted, “After the market close, ACHN provided an update...

In a report published Wednesday, Bank of America analyst Rachel McMinn downgraded the rating on ViroPharma (NASDAQ: VPHM) from Neutral to Underperform, but reiterated the $34.00 price target. In the report, Bank of America noted, “VPHM shares have increased 33% in response to a media article...

In a report published Wednesday, Bank of America analyst Rachel McMinn reiterated a Buy rating on Incyte Corporation (NASDAQ: INCY), and raised the price target from $31.00 to $36.00. In the report, Bank of America noted, “INCY announced top-line Phase 2 results for its marketed Jak inhibitor,...

In a report published Friday, Bank of America analyst Rachel McMinn downgraded Merrimack Pharmaceuticals (NASDAQ: MACK) from Buy to Neutral, and lowered the price target from $13.00 to $6.00. In the report, Bank of America noted, “We are downgrading MACK from Buy to Neutral and lowering our PO...

In a report published on Friday, Bank of America analyst Rachel McMinn downgraded ViroPharma (NASDAQ: VPHM) from Buy to Neutral and maintained a price target of $34. In the report, Bank of America stated, "Downgrading from BUY to Neutral Following 2Q results and a disappointing setback for subQ...

In a report published Monday, Bank of America analyst Rachel McMinn initiated coverage on bluebird bio (NASDAQ: BLUE) with a Buy rating and $42.00 price target. In the report, Bank of America noted, “We are initiating on bluebird bio (BLUE) with a $42 PO and Buy rating. BLUE is a biotechnology...

In a report published Friday, Bank of America analyst Rachel McMinn reiterated an Underperform rating and $3.00 price target on Idenix Pharmaceuticals (NASDAQ: IDIX). In the report, Bank of America noted, “Last evening IDIX announced that the FDA has put clinical development of its early-stage...